Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 44.00 NGN
Change Today 0.00 / 0.00%
Volume 87.4K
As of 9:30 AM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline consumer nig (GLAXOSMI) Snapshot

Open
46.20
Previous Close
44.00
Day High
46.20
Day Low
44.00
52 Week High
07/8/14 - 56.00
52 Week Low
01/19/15 - 31.99
Market Cap
52.6B
Average Volume 10 Days
311.2K
EPS TTM
1.28
Shares Outstanding
1.2B
EX-Date
05/14/15
P/E TM
34.4x
Dividend
0.60
Dividend Yield
1.36%
Current Stock Chart for GLAXOSMITHKLINE CONSUMER NIG (GLAXOSMI)

Related News

No related news articles were found.

glaxosmithkline consumer nig (GLAXOSMI) Related Businessweek News

No Related Businessweek News Found

glaxosmithkline consumer nig (GLAXOSMI) Details

GlaxoSmithKline Consumer Nigeria Plc manufactures, markets, and distributes a range of consumer healthcare and pharmaceutical products in Nigeria. The company operates through two segments, Consumer Healthcare and Pharmaceuticals. It offers consumer healthcare products, including oral healthcare products for family care, and sensitivity and bleeding gums; wellness products, such as pain management, and gastro-intestinal and respiratory health products, as well as multivitamins; and nutritional healthcare products comprising functional beverages and family nutritions primarily under the Panadol, Andrews Liver Salt, Macleans, Sensodyne, Phensic, Lucozade, and Ribena brands. The company also provides pharmaceutical products comprising prescription drugs for the treatment of asthma, malaria, depression, migraine, diabetes, heart failure, digestive conditions, and cancer; and vaccines to protect against illnesses, such as hepatitis A and B, diphtheria, tetanus, whooping cough, typhoid, influenza, and cervical cancer under the Ampiclox, Amoxil, Augmentin, Zentel, and Halfan brands. The company was formerly known as Beecham Limited. GlaxoSmithKline Consumer Nigeria Plc was incorporated in 1971 and is based in Lagos, Nigeria.

412 Employees
Last Reported Date: 04/1/15
Founded in 1971

glaxosmithkline consumer nig (GLAXOSMI) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

glaxosmithkline consumer nig (GLAXOSMI) Key Developments

GlaxoSmithKline Consumer Nigeria Plc to Report Q3, 2014 Results on Oct 22, 2014

GlaxoSmithKline Consumer Nigeria Plc announced that they will report Q3, 2014 results on Oct 22, 2014

GlaxoSmithKline Consumer Nigeria Plc Announces Management Changes

GlaxoSmithKline Consumer Nigeria Plc has announced the appointment of an interim Managing Director, Justin Korteasa following the voluntary resignation of Mr. Chidi Okoro, as the company's Managing Director with effect from March 15, 2014. Until a new candidate is confirmed for the role, the GSK Nigeria Board has appointed Mr. Justin Korte as a Director and the General Manager. Korte joined GSK from Gillette in early 2005, and has progressed through national accounts and national sales roles. After running his own business in 2008, Justin returned to head GSK's Southern Africa business as Group Country Manager. He was promoted in 2011 to Sales Director, Africa.

GlaxoSmithKline To Continue With Its Plan To Acquire Nigerian Unit

GlaxoSmithKline plc (LSE:GSK) may continue with its plans to acquire a majority stake in its Nigerian unit after suspending the plan four months ago. Chidi Okoro, Chief Executive Officer of GlaxoSmithKline Consumer Nigeria Plc (NGSE:GLAXOSMITH), said that the plan by GSK to increase equity in its Nigerian unit was only suspended and will come up later when all parties involved reach an agreement. Chidi said, "Our focus is that if it has to be done, it's done right." GSK, in July 2013, proposed to raise its stake in the Nigerian business to 80% from 46.4%, in a transaction estimated at $98 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GLAXOSMI:NL 44.00 NGN 0.00

GLAXOSMI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $19.71 USD -0.06
AstraZeneca PLC 4,406 GBp -67.50
Merck & Co Inc $59.22 USD -0.16
Sumitomo Dainippon Pharma Co Ltd ¥1,410 JPY 0.00
Teva Pharmaceutical Industries Ltd $60.38 USD -0.67
View Industry Companies
 

Industry Analysis

GLAXOSMI

Industry Average

Valuation GLAXOSMI Industry Range
Price/Earnings 34.4x
Price/Sales 1.7x
Price/Book 4.0x
Price/Cash Flow 34.5x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE CONSUMER NIG, please visit www.gsk.com/ng. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.